SVRA

Savara Inc

4.64

Nov 13 • 3:59 PM ET -0.08 (-1.69%)

4.70

Aftermarket • 7:44 PM ET +0.06 (1.34%)

Healthcare Biotechnology USA Small NASD

Peers: AVLN INSM MNKD RARE PLRX ZVRA VCRE PHAR ARMP PULM

| Held by: VTI IWM XBI VXF IWO VTWO SCHA IBB LFSC IWC

Scroll to Statements

Index	RUT
Market Cap	1.02B
Enterprise Value	924.40M
Income	-152.74M
Sales	0.00M
Book/sh	0.52
Cash/sh	0.59
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	70
IPO	Oct 16, 2000

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	8.84
P/C	7.90
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.55
Current Ratio	8.55
Debt/Eq	0.28
LT Debt/Eq	0.28
Option/Short	Yes / Yes

EPS (ttm)	-0.61
EPS next Y	-0.39
EPS next Q	-0.17
EPS this Y	-19.80%
EPS next Y	38.08%
EPS next 5Y	-
EPS past 3/5Y	-28.87% 8.57%
Sales past 3/5Y	- -
EPS Y/Y TTM	-13.83%
Sales Y/Y TTM	-
EPS Q/Q	-23.79%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-12.28% -

Insider Own	49.88%
Insider Trans	-0.36%
Inst Own	64.90%
Inst Trans	1.10%
ROA	-102.90%
ROE	-151.05%
ROIC	-110.61%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.96%
SMA50	-5.97%
SMA200	-13.01%
Trades

Shs Outstand	205.54M
Shs Float	110.58M
Short Float	29.19%
Short Ratio	14.30
Short Interest	32.27M
52W High	7.01 -33.76%
52W Low	4.03 15.14%
Volatility	6.46% 7.00%
ATR (14)	0.30
RSI (14)	45.95
Beta	0.31
Rel Volume	1.43
Avg Volume	2.26M
Volume	3,231,427

Perf Week	-3.93%
Perf Month	-2.11%
Perf Quarter	-13.59%
Perf Half Y	-7.75%
Perf YTD	-23.05%
Perf Year	8.92%
Perf 3Y	34.10%
Perf 5Y	310.62%
Perf 10Y	-16.83%
Recom	1.00
Target Price	11.06
Prev Close	4.72
Price	4.64
Change %	-1.69%

Consensus

Strong Buy

Avg. Price Target

$11.06

Implied Upside

+138.4%

Analysts11incl. previous ratings

Rating Distribution8 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 12, 2026	Resumed	HH.C. Wainwright	Buy	$10	+115.5%
Oct 07, 2026	Initiated	JJP Morgan	Overweight	$12	+158.6%
Apr 24, 2026	Resumed	OOppenheimer	Outperform	$9 → $11	+137.1%
Oct 20, 2025	Initiated	WWells Fargo	Overweight	$7	+50.9%
Aug 15, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$5	+7.8%
May 29, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral	$2	-56.9%
Dec 20, 2024	Initiated	WWells Fargo	Overweight	$8	+72.4%
Nov 13, 2024	Downgrade	EEvercore ISI	Outperform → In-line	$7 → $5	+7.8%
Feb 15, 2024	Initiated	JJMP Securities	Mkt Outperform	$8	+72.4%
Nov 07, 2023	Initiated	GGuggenheim	Buy	$7	+50.9%
May 16, 2023	Upgrade	JJefferies	Hold → Buy	$2 → $4	-13.8%
Mar 31, 2023	Downgrade	JJefferies	Buy → Hold	$2	-56.9%
Mar 16, 2021	Initiated	PPiper Sandler	Overweight	$7	+50.9%
Mar 15, 2021	Initiated	OOppenheimer	Outperform	$4	-13.8%
Jun 13, 2019	Reiterated	HH.C. Wainwright	Buy	$22 → $6	+29.3%
Jun 13, 2019	Downgrade	LLadenburg Thalmann	Buy → Neutral	$21 → $3	-35.3%
Jun 13, 2019	Downgrade	JJMP Securities	Mkt Outperform → Mkt Perform
Aug 13, 2018	Resumed	RROTH Capital	Neutral	$12	+158.6%
Jan 03, 2018	Initiated	LLadenburg Thalmann	Buy	$35	+654.3%
Sep 27, 2017	Resumed	RROTH Capital	Buy	$40	+762.1%

Nov-12-26 03:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.41%
Oct-21-26 01:10PM	Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment (Business Wire)
Oct-12-26 04:05PM	Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 (Business Wire)
Oct-11-26 12:43PM	Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside (TIKR)
Aug-24-26 04:05PM	Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 (Business Wire)
04:05PM	Loading…
Aug-20-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-11-26 04:05PM	Savara Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Aug-07-26 11:39AM	What Insmed Stock's Premium Is Actually Buying (Trefis)
Jul-30-26 08:05AM	Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 (Business Wire)
Jun-12-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jun-08-26 04:05PM	Savara Announces Chief Financial and Administrative Officer Transition (Business Wire)
May-27-26 04:05PM	Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference (Business Wire)
May-20-26 08:15AM	Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 (Business Wire) +7.63%
May-19-26 02:15PM	Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
May-18-26 02:55PM	Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
04:05PM	Loading…
May-12-26 04:05PM	Savara Reports First Quarter Financial Results and Provides Business Update (Business Wire)
May-11-26 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference (Business Wire)
Apr-17-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Apr-15-26 04:05PM	Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Apr-14-26 08:05AM	Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference (Business Wire)
Apr-07-26 08:05AM	Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Mar-30-26 08:05AM	Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Mar-13-26 08:05AM	Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update (Business Wire)
Mar-06-26 04:05PM	Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Mar-04-26 04:05PM	Savara Announces Participation in 2026 Citizens Life Sciences Conference (Business Wire)
Mar-01-26 07:36PM	Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears (MarketBeat)
Feb-20-26 04:15PM	Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Feb-15-26 11:03AM	Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit (MarketBeat)
Feb-13-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Feb-04-26 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) -5.30%
08:05AM	Loading…
Jan-27-26 08:05AM	Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
Jan-16-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-08-26 04:05PM	PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* (Business Wire)
Dec-22-25 08:30AM	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire) +6.94%
Dec-17-25 08:05AM	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-11-25 08:05AM	Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* (Business Wire)
Dec-02-25 08:05AM	Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System (Business Wire)
Dec-01-25 01:23PM	Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences (Insider Monkey) -7.15%
Nov-20-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.35%
Nov-12-25 04:05PM	Savara Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire)
02:56AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-31-25 04:05PM	Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M (Business Wire)
Oct-30-25 11:29PM	What Does Wall Street Think About Savara Inc. (SVRA)? (Insider Monkey)
Oct-29-25 09:43PM	Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants (Business Wire)
04:07PM	Savara Announces Proposed Public Offering (Business Wire)
04:01PM	Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
11:57AM	Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections (Insider Monkey)
Oct-17-25 08:05AM	Savara Announces Chief Medical Officer (CMO) Transition (Business Wire)
Oct-13-25 04:59PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-10-25 09:00AM	Savara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRA (PR Newswire)
Oct-07-25 07:40AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-02-25 04:05PM	Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 (Business Wire)
Sep-29-25 02:00AM	Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-25-25 04:37PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Sep-24-25 04:25PM	Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 (Newsfile)
Sep-23-25 10:53AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SVRA (Business Wire)
Sep-20-25 02:43AM	Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity (Insider Monkey)
Sep-11-25 04:18PM	Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025 (Newsfile) -6.27%
Sep-02-25 09:00AM	Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis (Business Wire)
Aug-26-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.41%
Aug-23-25 04:16AM	Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough (Insider Monkey)
Aug-20-25 05:15PM	New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Aug-18-25 08:05AM	Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 (Business Wire)
Aug-13-25 08:05AM	Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
Jul-18-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lowrance David L	Chief Financial Officer	Jun 22 '26	Option Exercise	1.76	580,187	1,021,116	983,947	Jun 22 08:18 PM
Lowrance David L	Chief Financial Officer	Jun 22 '26	Sale	5.68	394,528	2,241,432	536,032	Jun 22 08:18 PM
Lowrance David L	Officer	Jun 22 '26	Proposed Sale	5.65	394,528	2,229,000		Jun 22 03:09 PM
Lowrance David L	Chief Financial Officer	Mar 18 '26	Option Exercise	1.60	366,747	588,455	552,550	Mar 20 04:16 PM
McCracken Joseph S	Director	Feb 16 '26	Option Exercise	1.76	1,807	3,180	302,644	Feb 17 05:30 PM
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19 05:00 PM
RAMSAY DAVID A	Director	Dec 18 '25	Proposed Sale	6.11	20,000	122,200		Dec 18 11:17 AM
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04 06:55 PM

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Yardley, PA.

M.B.A.Mr. Matthew Pauls J.D.

COO & CFOMr. Robert Matthew Lutz M.B.A.

Ph.D.Dr. Yasmine Wasfi M.D.

Chief Legal OfficerMs. Kate McCabe J.D.

Chief People OfficerMs. Megan Carpenter

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

SVRA

Savara Inc

Upgrade your Finviz experience

All the Features.
Half the Price.